Transplant recipients that are deficient for IL-33 are protected from GVHD and administration of IL-33 in the early post transplantation period (days 3–7 post-transplant) was shown to exacerbate this disease (79), suggesting a proinflammatory role. The gene discussed is IL33; the disease is graft versus host disease.